CTAD 2025 | Barriers and strategies to overcome equitable participation in Alzheimer’s disease clinical trials

Sid O’Bryant, PhD, Institute for Translational Research at UNT Health, Fort Worth, TX, discusses the most significant barriers preventing equitable participation in Alzheimer’s disease clinical trials, and strategies to overcome these. Dr O’Bryant emphasizes that the barriers to inclusion lie within the scientific community, citing issues such as access to specialty clinics, insurance, and stigma. This interview took place at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.